EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Could obinutuzumab be the new therapy for adults with primary membranous nephropathy?

Cristián Juanet, João Venda, Federico Yandian, Fernando Caravaca-Fontán, Fernando C Fervenza

Expert Review of Clinical Pharmacology · 05.11.2026

DOI: 10.1080/17512433.2026.2761222 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Expert Review of Clinical Pharmacology, online erschienen am 05.11.2026. Verfasst von Cristián Juanet und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Pontificia Universidad Católica de Chile, Santiago, Chile. Die Arbeit nennt 110 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Membranous nephropathy (MN) is the most common cause of nephrotic syndrome in adults. Anti-CD20 therapy is first-line when immunosuppression is indicated. However, a non-negligible proportion of patients fails to respond to rituximab, through mechanisms that include urinary drug loss and escape of tissue-resident B cells or long-lived plasma cells. Obinutuzumab, a glycoengineered humanized type II anti-CD20 antibody producing deeper, more sustained B-cell depletion, is a candidate to overcome these limitations. AREAS COVERED: We review the treatment landscape and unmet needs in primary MN; the chemistry, pharmacodynamics, pharmacokinetics and rationale of obinutuzumab; its clinical efficacy, including the MAJESTY trial; its safety profile; the competitive environment; and its regulatory status. PubMed was searched without date restrictions up to October 2026. EXPERT OPINION: Obinutuzumab is effective in primary MN, with the clearest indications being high anti-phospholipase A2 receptor (anti-PLA2R) titers, high-risk disease, severe rituximab hypersensitivity and rituximab-refractory disease. Key questions concern how best to use it: its pharmacokinetics in the nephrotic state are uncharacterized, and response-adapted dosing instead of the fixed four-dose regimen requires prospective validation. Persistent immunologic activity despite confirmed depletion argues for plasma cell-directed therapy. Standardized definitions of immunologic remission and resistance remain essential to generate better comparative evidence.

Schlagwörter

Stichwörter der Autor:innen

Anti-PLA2R antibodiesMembranous nephropathyNephrotic syndromeObinutuzumabRituximabanti-CD 20 therapy

Autor:innen und Institutionen

  • Department of Nephrology, Pontificia Universidad Católica de Chile, Santiago, Chile.
  • Department of Nephrology, Coimbra University Hospital, ULS Coimbra, Coimbra, Portugal.
  • Department of Nephrology, University of Coimbra, Coimbra, Portugal.
  • Department of Nephrology, Médica Uruguaya, Montevideo, Uruguay.
  • Department of Nephrology, Instituto de Investigación Hospital "12 de Octubre" (imas12), Madrid, Spain.
  • Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.

Zitieren

APA

Juanet, C., Venda, J., Yandian, F., Caravaca-Fontán, F., & Fervenza, F. C. (2026). Could obinutuzumab be the new therapy for adults with primary membranous nephropathy?. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2026.2761222

Vancouver

Juanet C, Venda J, Yandian F, Caravaca-Fontán F, Fervenza FC. Could obinutuzumab be the new therapy for adults with primary membranous nephropathy?. Expert Review of Clinical Pharmacology. 2026. doi:10.1080/17512433.2026.2761222

BibTeX
@article{Juanet2026,
  author = {Juanet, Cristián and Venda, João and Yandian, Federico and Caravaca-Fontán, Fernando and Fervenza, Fernando C},
  title = {Could obinutuzumab be the new therapy for adults with primary membranous nephropathy?},
  journal = {Expert Review of Clinical Pharmacology},
  year = {2026},
  doi = {10.1080/17512433.2026.2761222}
}
Kostenlos starten →